CD274 and non-small cell lung carcinoma: Furthermore, the SKYSCRAPER-01 study (NCT04294810), which assessed tiragolumab plus atezolizumab (Tecentriq) vs. atezolizumab alone for patients with PD-L1-high locally advanced or metastatic NSCLC, did not meet the co-primary endpoint of PFS, though OS was immature [21, 24].